Newsroom
June 27, 2016
During the summer months, various factors may result in ED visits by asthmatics and diabetics, said Rosemarie Ramos, Ph.D., M.P.H., of the School of Medicine at the Health Science Center.
May 26, 2016
VeroScience LLC, is pleased to announce that independent research conducted by Dr. Ralph DeFronzo and his team at UT Health Science Center at San Antonio (“Health Science Center“) has continued to delineate metabolic targets of VeroScience’s Cycloset® in reducing hyperglycemia in type 2 diabetes mellitus (T2DM) patients. The study has also identified positive influences of the […]
April 18, 2016
More than 14 percent of adults in San Antonio and Bexar County had been diagnosed with Type-1 or Type-2 diabetes in 2014 – which is the most recent data. That is 4 percent higher than the state average and – more troubling for medical professionals – nearly 3 percent higher than it was two years […]
April 8, 2016
Scientists have uncovered a way to improve liver metabolism for those with non-alcoholic fatty liver disease by using an acute dose of an existing diabetes treatment. Read the full story at Science Daily
March 22, 2016
The protective effect of pioglitazone on type 2 diabetes prevention observed in adults with impaired glucose tolerance diminishes in the months after discontinuing therapy, with participants randomly assigned the drug progressing to diabetes at a rate similar to those assigned placebo, according to an analysis of the ACT NOW study. Read the full story at […]
February 15, 2016
The study, Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor, has been published in Diabetes, Obesity and Metabolism. Researchers looked at the recently completed EMPA-REG study, which demonstrated that Empagliflozin significantly decreased major adverse cardiac events (MACE) in people with type 2 diabetes, deemed high risk. Read the full story at The Diabetes […]